Abstract:Background: The ex vivo production of CD34+ hematopoietic progenitor cells from human bone-marrow mesenchymal stromal cells derived induced pluipotent stem cells (iPSCs) could serve as a feasible way to study patient-specific hematological disease from the perspective of hematopoietic differentiation. Different studies using virus-based or virus-free methods to reprogramming somatic cells into iPSCs by using fewer than four transcription factors, of which have the potential to differentiation in CD34+ hematopoietic progenitor cells. In this study, we demonstrate the generation of putative iPS cells from BMSCs with single OCT4 by plasmid transfection, which can differentiate into hematopoietic progenitor cells in defined culture system.Objective: To generate induced pluripotent stem cells (iPSCs) from bone marrow stromal cells (BMSCs) using a plasmid pcDNA3.1 constructed with a single transcription factor gene OCT4 (pcDNA3.1-OCT4) and to evaluate the hematopoietic differentiation potential of the putative BMSCs-iPSCs.Methods: BMSCs with ectopic high expression of OCT4 (BMSCs-OCT4) previously established by our group were cultured in traditional human ESC medium. Colonies with characteristic embryonic stem (ES) cell morphologies were selected and expanded in vitro. The undifferentiated status of putative BMSCs-iPSCs was confirmed by alkaline phosphatase (ALP) staining, telomerase activity assay, pluripotent marker expression and differentiation in vitro to form EBs and in vivo teratoma formation. The expression of pluripotent markers and ES markers were verified by RT-PCR, flow cytometry (FCM) and cellular immunofluorescence assay (CIFA). The hematopoietic differentiation potential into CD34+ progenitor cells by exposure to a defined culture system supplemented with a cocktail of hematopoietic growth factors was evaluated, of which the expression was confirmed by RT-PCR and FCM.Results: BMSCs were successfully reprogrammed into pluripotent stem cells resembling ESCs by introduction single transcription factor OCT4 gene constructed into the eukaryogenic plasmid pcDNA3.1. The putative BMSC-iPSCs were positive for ALP and telomerase activity, as well as the pluripotent stem cell markers including TRA-1-60, SSEA4, TRA-1-81, SOX2 and NANOG as detected by FCM and CIFA. Moreover, the above MSCs-OCT4 could form EBs ex vivo and express ectoderm (TUBB3+, WNT1+), mesoderm (Brachyury+, TBX20+), and endoderm (SPARC+) genes. By treatment with a cocktail containing BMP4 (50ng/ml), IL-3 (10ng/ml), IL-6 (10ng/ml), Flt-3 Ligand (300ng/ml), SCF (300ng/ml) and G-CSF (50ng/ml), the proportion of CD34+ progenitor cells increased from 0.93±0.46% in untransfected parental BMSCs and 1.58±1.29% in undifferentiated BMSC-iPS cells to 16.16±1.27% and 25.40±3.08% in day 14 and 21 differentiated BMSC-iPS cells, respectively. Moreover, the proportion of CD34+ progenitor cells were higher in the group with diverse concentration of growth factor cocktail induction, the proportion of CD34+ cells reached 31.39±3.60% and 73.68±6.63% in day 14 and 21 differentiated BMSC-iPS cells, respectively.Conclusion: In this study, we have clearly demonstrated the generation of putative iPS cells (or partly reprogrammed iPSCs from BMSCs with ectopic high expression of OCT4 by plasmid transfection). The BMSCs-derived iPSCs display the typical morphology and growth pattern as iPS cells when they are maintained in undifferentiated pluripotent state. Moreover, the putative BMSCs-derived iPSCs can differentiate into hematopoietic progenitor cells in defined culture system containing a cocktail of six or seven growth factors. Our findings provide a feasible way to generate hematopoietic progenitor cells using patient-specific iPSCs generated by plasmid transfection for hematological disease modeling.

A Serum- and Feeder-Free System to Generate CD4 and Regulatory T Cells from Human iPSCs

Abstract 11: Development of innovative off-the-shelf cancer immunotherapies with iPSC-derived CD8-positive T-cells

3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells

Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells

Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation

iPSC-Derived CD4 T Cell Generation and Investigation of CD4/CD8 T Cell Lineage Choice

Single OCT4 gene introduced into human bone-marrow derived mesenchymal stromal cells can generate putative iPS cells with the potential to differentiate into CD34+ hematopoietic progenitor cells ex vivo

Optimizing in vitro T cell differentiation by using induced pluripotent stem cells with GFP‐RUNX1 and mCherry‐TCF7 labelling

Generation of immune cells from induced pluripotent stem cells (iPSCs): Their potential for adoptive cell therapy

Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells

Abstract 39: Preclinical in vitro and in vivo evaluation of CD8αβ+ CD19 CAR iPSCs T cells generated in a TCR signal-independent manner using DLL4/VCAM-coupled microbeads

Introduction of OCT4 into Human Bone-Marrow Derived Mesenchymal Stromal Cells Generates Putative Ips Cells with the Potential to Differentiate into CD34+ Hematopoietic Progenitor Cells Ex Vivo

A Scalable, Off-the-Shelf, and Cost-Effective NK Cell Manufacturing Platform for Developing NK Cell-Based Immunotherapy

Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells

Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy

Efficient Derivation and Genetic Modifications of Human Pluripotent Stem Cells on Engineered Human Feeder Cell Lines.

Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells

Generation of Human iPSCs by Episomal Reprogramming of Skin Fibroblasts and Peripheral Blood Mononuclear Cells

Efficient production of erythroid, megakaryoid and myeloid cells, using single cell-derived iPSC colony differentiation

A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors

Generation of Human iPSCs by Protein Reprogramming and Stimulation of TLR3 Signaling